Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merus N.V. - Common Shares (NQ:MRUS)

96.89 +0.09 (+0.10%)
Streaming Delayed Price Updated: 3:35 PM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merus N.V. - Common Shares

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Merus to Present at BofA Securities 2025 Health Care Conference
From Merus N.V.
Via GlobeNewswire
News headline image
Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
News headline image
Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting
From Merus N.V.
Via GlobeNewswire
News headline image
What's Going On With Merus Stock Monday? ↗
Merus announced a research collaboration and license agreement with Biohaven. 
Via Benzinga
News headline image
Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
From Merus N.V.
Via GlobeNewswire
News headline image
Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
News headline image
Merus to Present at Upcoming Investor Conferences
From Merus N.V.
Via GlobeNewswire
News headline image
Merus Shares Are Up Today: What's Going On? ↗
Shares of Merus N.V. (NASDAQ: MRUS) are trading higher Tuesday after the company announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) for... 
Via Benzinga
News headline image
Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
This marks the second BTD for petosemtamab in HNSCC 
From Merus N.V.
Via GlobeNewswire
News headline image
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit
From Merus N.V.
Via GlobeNewswire
News headline image
New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer
From Merus N.V.
Via GlobeNewswire
News headline image
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs
From Merus N.V.
Via GlobeNewswire
News headline image
TD Synnex, Walgreens, Savers Value Village And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC
From Merus N.V.
Via GlobeNewswire
News headline image
Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC
From Merus N.V.
Via GlobeNewswire
News headline image
Merus Scores Its First FDA Approval For Lung Cancer Drug ↗
FDA approves Merus' Bizengri as the first treatment for advanced NRG1 fusion-positive cancers. U.S. peak sales are estimated at $16.5 million. 
Via Benzinga
News headline image
Jim Cramer: This Health Care Stock Is 'Very, Very Speculative' ↗
Jim Cramer called Allison Transmission a "storied company... terrific. It does great." 
Via Benzinga
News headline image
Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study
From Merus N.V.
Via GlobeNewswire
News headline image
Merus Licenses US Commercialization Rights For Cancer Potential Zenocutuzumab, Analyst Highlight Merus' Pipeline ↗
Merus partners with Partner Therapeutics for U.S. rights to Zeno in NRG1+ cancer. Updated petosemtamab data emerge as a key focus for analysts. 
Via Benzinga
News headline image
XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer
From Merus N.V.
Via GlobeNewswire
News headline image
Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024
From Merus N.V.
Via GlobeNewswire
News headline image
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Merus to Present at Upcoming Investor Conferences
From Merus N.V.
Via GlobeNewswire
News headline image
Merus Receives FDA extension of PDUFA for zenocutuzumab
From Merus N.V.
Via GlobeNewswire
News headline image
Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
News headline image
Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC
From Merus N.V.
Via GlobeNewswire
News headline image
Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024
Petosemtamab in 2L+ HNSCC interim clinical data selected for rapid oral presentation 
From Merus N.V.
Via GlobeNewswire
News headline image
Merus to Present at Canaccord Genuity’s 44th Annual Growth Conference
From Merus N.V.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.